Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester Massachusetts, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Follow-Up Questions
Qui est le CEO de Mustang Bio Inc ?
Dr. Manuel Litchman est le President de Mustang Bio Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action MBIO ?
Le prix actuel de MBIO est de $1.65, il a increased de 1.85% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Mustang Bio Inc ?
Mustang Bio Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Mustang Bio Inc ?
La capitalisation boursière actuelle de Mustang Bio Inc est de $11.9M
Est-ce que Mustang Bio Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Mustang Bio Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
